CN115038497A - TGF-β-RII结合蛋白质 - Google Patents

TGF-β-RII结合蛋白质 Download PDF

Info

Publication number
CN115038497A
CN115038497A CN202080094188.4A CN202080094188A CN115038497A CN 115038497 A CN115038497 A CN 115038497A CN 202080094188 A CN202080094188 A CN 202080094188A CN 115038497 A CN115038497 A CN 115038497A
Authority
CN
China
Prior art keywords
antibody
seq
amino acid
acid sequence
sequence shown
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080094188.4A
Other languages
English (en)
Chinese (zh)
Inventor
马克·思罗斯比
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merus BV
Original Assignee
Merus BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus BV filed Critical Merus BV
Priority to CN202211726434.0A priority Critical patent/CN116375869A/zh
Priority to CN202211726462.2A priority patent/CN116199780A/zh
Publication of CN115038497A publication Critical patent/CN115038497A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080094188.4A 2019-12-24 2020-12-22 TGF-β-RII结合蛋白质 Pending CN115038497A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202211726434.0A CN116375869A (zh) 2019-12-24 2020-12-22 TGF-β-RII结合蛋白质
CN202211726462.2A CN116199780A (zh) 2019-12-24 2020-12-22 TGF-β-RII结合蛋白质

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2024576 2019-12-24
NL2024576 2019-12-24
PCT/NL2020/050813 WO2021133167A1 (en) 2019-12-24 2020-12-22 Tgf-beta-rii binding proteins

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202211726434.0A Division CN116375869A (zh) 2019-12-24 2020-12-22 TGF-β-RII结合蛋白质
CN202211726462.2A Division CN116199780A (zh) 2019-12-24 2020-12-22 TGF-β-RII结合蛋白质

Publications (1)

Publication Number Publication Date
CN115038497A true CN115038497A (zh) 2022-09-09

Family

ID=69700252

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202080094188.4A Pending CN115038497A (zh) 2019-12-24 2020-12-22 TGF-β-RII结合蛋白质
CN202211726462.2A Pending CN116199780A (zh) 2019-12-24 2020-12-22 TGF-β-RII结合蛋白质
CN202211726434.0A Pending CN116375869A (zh) 2019-12-24 2020-12-22 TGF-β-RII结合蛋白质

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202211726462.2A Pending CN116199780A (zh) 2019-12-24 2020-12-22 TGF-β-RII结合蛋白质
CN202211726434.0A Pending CN116375869A (zh) 2019-12-24 2020-12-22 TGF-β-RII结合蛋白质

Country Status (14)

Country Link
US (1) US20250270331A1 (enExample)
EP (2) EP4081306A1 (enExample)
JP (3) JP7633259B2 (enExample)
KR (2) KR20230145542A (enExample)
CN (3) CN115038497A (enExample)
AR (2) AR120914A1 (enExample)
AU (2) AU2020412201A1 (enExample)
BR (1) BR112022012522A2 (enExample)
CA (1) CA3165605A1 (enExample)
IL (2) IL294181A (enExample)
MX (2) MX2022007919A (enExample)
PH (1) PH12022551527A1 (enExample)
TW (2) TW202128747A (enExample)
WO (1) WO2021133167A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024542879A (ja) * 2021-11-19 2024-11-18 メルス ナムローゼ フェンノートシャップ Ｐｄ－１およびｔｇｆ－ｂｒｉｉ結合ドメインを含む多重特異性結合部位
KR20250123916A (ko) 2022-12-20 2025-08-18 메뤼스 엔.페. FAP 결합 도메인 및 FAP와 TGF-βRII에 결합하는 이중특이성 결합 모이어티

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001206899A (ja) 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
CN105884893A (zh) 2002-07-18 2016-08-24 莫鲁斯有限公司 抗体混合物的重组生产
PL3456190T3 (pl) 2008-06-27 2022-06-06 Merus N.V. Wytwarzające przeciwciała transgeniczne zwierzę z gatunku myszy
JO3096B1 (ar) 2008-11-07 2017-03-15 Imclone Llc الأجسام المضادة لمستقبل ii مضاد tgfb
CA2823104A1 (en) 2011-01-06 2012-07-12 Glaxo Group Limited Ligands that bind tgf-beta receptor ii
PL2900694T3 (pl) 2012-09-27 2018-12-31 Merus N.V. Dwuswoiste przeciwciała igg jako aktywatory komórek t
EP3324996A4 (en) * 2015-07-22 2019-04-17 Scholar Rock, Inc. GDF11 BINDING PROTEINS AND USES THEREOF
TW201825519A (zh) * 2016-10-18 2018-07-16 美商美國禮來大藥廠 TGFβ受體II抗體
BR112020019795A2 (pt) 2018-03-30 2021-01-05 Merus N.V. Anticorpo multivalente

Also Published As

Publication number Publication date
MX2024002182A (es) 2024-05-03
KR20220117267A (ko) 2022-08-23
PH12022551527A1 (en) 2024-01-29
CN116375869A (zh) 2023-07-04
CA3165605A1 (en) 2021-07-01
EP4269433A2 (en) 2023-11-01
MX2022007919A (es) 2022-07-27
AR130991A2 (es) 2025-02-05
CN116199780A (zh) 2023-06-02
AR120914A1 (es) 2022-03-30
IL294181A (en) 2022-08-01
AU2020412201A1 (en) 2022-07-14
KR20230145542A (ko) 2023-10-17
TW202128747A (zh) 2021-08-01
US20250270331A1 (en) 2025-08-28
JP7633259B2 (ja) 2025-02-19
BR112022012522A2 (pt) 2022-09-06
AU2023200779A1 (en) 2023-03-09
EP4269433A3 (en) 2024-05-22
JP2023508202A (ja) 2023-03-01
EP4081306A1 (en) 2022-11-02
IL304317A (en) 2023-09-01
JP2025083342A (ja) 2025-05-30
TW202417513A (zh) 2024-05-01
WO2021133167A1 (en) 2021-07-01
JP2023076596A (ja) 2023-06-01

Similar Documents

Publication Publication Date Title
US20230151112A1 (en) Immunoactivating antigen-binding molecule
CN111683970B (zh) C-kit结合剂
US11525005B2 (en) Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof
US20230357398A1 (en) Novel human antibodies binding to human cd3 epsilon
JP2025083342A (ja) ＴＧＦ－βＲＩＩ結合タンパク質
WO2021018035A1 (zh) 人源化抗il17a抗体及其应用
WO2021013080A1 (zh) 人源化抗vegf单克隆抗体
WO2021143914A1 (zh) 一种激活型抗ox40抗体、生产方法及应用
HK40094429A (en) Tgf-beta-rii binding proteins
BR122023027661A2 (pt) Proteínas de ligação de tgf-beta-rii
RU2779128C2 (ru) Антитело к cd40, его антигенсвязывающий фрагмент и его медицинское применение
TW202430547A (zh) 結合至nkg2a及pd-l1之藥劑及其用途
TW202436338A (zh) Nkg2a結合劑及其用途
TW202436350A (zh) 抗ｌｉｌｒｂ１及／或抗ｌｉｌｒｂ２抗體及其等用途
WO2025228351A1 (zh) 抗体，抗体药物偶联物及其用途
TW202214705A (zh) 抗tigit抗體及雙抗體和它們的應用
HK40066221B (zh) 人源化抗vegf fab抗体片段及其用途
HK40066221A (zh) 人源化抗vegf fab抗体片段及其用途
CN119487070A (zh) 靶向cd117的抗体
HK40066235B (zh) 人源化抗il17a抗体及其应用
BR112021003089A2 (pt) anticorpos biespecíficos anti-pd-l1/anti-lag3 e seus usos
HK40066235A (zh) 人源化抗il17a抗体及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: Mark Throsby

Inventor after: Lindsay Clost

Inventor after: De Kruif Cornelis Adrian

Inventor before: Mark Throsby